Spero Therapeutics (NASDAQ:SPRO) and Sernova (OTCMKTS:SEOVF) Head-To-Head Survey (2024)

Sernova (OTCMKTS:SEOVF – Get Free Report) and Spero Therapeutics (NASDAQ:SPRO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Earnings and Valuation

This table compares Sernova and Spero Therapeutics’ gross revenue, earnings per share and valuation.

Spero Therapeutics has higher revenue and earnings than Sernova. Sernova is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

25.6% of Spero Therapeutics shares are held by institutional investors. 4.5% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Sernova and Spero Therapeutics, as provided by MarketBeat.

Sernova currently has a consensus price target of $1.50, indicating a potential upside of 669.63%. Spero Therapeutics has a consensus price target of $7.00, indicating a potential upside of 401.79%. Given Sernova’s higher possible upside, research analysts plainly believe Sernova is more favorable than Spero Therapeutics.

Profitability

This table compares Sernova and Spero Therapeutics’ net margins, return on equity and return on assets.

Volatility & Risk

Sernova has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Summary

Spero Therapeutics beats Sernova on 10 of the 12 factors compared between the two stocks.

About Sernova

(Get Free Report)

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

About Spero Therapeutics

(Get Free Report)

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter.